Oryzon Genomics SA (ORY) — Cash Flow-to-Debt Ratio
Oryzon Genomics SA (ORY) has a Cash Flow-to-Debt Ratio of -0.09x as of June 2023, meaning its operating cash flow of €-2.41 Million could theoretically repay 0% of its total liabilities (€26.10 Million) in one year. Explore how much of Oryzon Genomics SA's assets are long-term investments to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Oryzon Genomics SA Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Oryzon Genomics SA across 13 annual periods. Also explore ORY total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Oryzon Genomics SA (2013–2025)
Year-by-year debt coverage analysis for Oryzon Genomics SA. For market capitalisation and broader financial context, see Oryzon Genomics SA market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.09x | €-2.36 Million | €26.68 Million | ▲ +66.4% |
| 2024 | -0.26x | €-5.69 Million | €21.67 Million | ▼ -1047.2% |
| 2023 | -0.02x | €-574.96K | €25.13 Million | ▲ +61.4% |
| 2022 | -0.06x | €-1.85 Million | €31.13 Million | ▲ +60.5% |
| 2021 | -0.15x | €-3.63 Million | €24.12 Million | ▲ +43.3% |
| 2020 | -0.27x | €-4.82 Million | €18.18 Million | ▲ +99.5% |
| 2019 | -49.56x | €-3.93 Million | €79.38K | ▼ -166006.5% |
| 2018 | -0.03x | €-666.09K | €22.33 Million | ▲ +83.1% |
| 2017 | -0.18x | €-4.71 Million | €26.61 Million | ▲ +4.6% |
| 2016 | -0.19x | €-5.01 Million | €27.02 Million | ▼ -565.5% |
| 2015 | 0.04x | €523.14K | €13.14 Million | ▼ -96.0% |
| 2014 | 1.00x | €12.13 Million | €12.16 Million | ▲ +15.4% |
| 2013 | 0.86x | €12.13 Million | €14.04 Million | — |